{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:50:37Z","timestamp":1767912637814,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s00482-012-1238-1","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T06:06:38Z","timestamp":1348812398000},"page":"609-619","source":"Crossref","is-referenced-by-count":6,"title":["Morbus Fabry","Fabry disease"],"prefix":"10.1007","volume":"26","author":[{"given":"N.","family":"\u00dc\u00e7eyler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"key":"1238_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30","journal-title":"Orphanet J Rare Dis"},{"key":"1238_CR2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","volume":"4","author":"Motabar","year":"2010","unstructured":"Motabar O, Sidransky E, Goldin E et\u00a0al (2010) Fabry disease\u2014current treatment and new drug development. Curr Chem Genomics 4:50\u201356","journal-title":"Curr Chem Genomics"},{"key":"1238_CR3","doi-asserted-by":"crossref","unstructured":"Saito S, Ohno K, Sakuraba H (2011) Fabry-database.org: database of the clinical phenotypes, genotypes and mutant alpha-galactosidase\u00a0A structures in Fabry disease. J\u00a0Hum Genet 56:467\u2013468","DOI":"10.1038\/jhg.2011.31"},{"key":"1238_CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ et\u00a0al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"1238_CR5","doi-asserted-by":"crossref","unstructured":"\u00dc\u00e7eyler N, He L, Sch\u00f6nfeld D et\u00a0al (2011) Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J\u00a0Peripher Nerv Syst 16:304\u2013314","DOI":"10.1111\/j.1529-8027.2011.00365.x"},{"key":"1238_CR6","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd et\u00a0al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"1238_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE et\u00a0al (2001) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711\u2013722","journal-title":"Am J Hum Genet"},{"key":"1238_CR8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","volume":"23","author":"Lockman","year":"1973","unstructured":"Lockman LA, Hunninghake DB, Krivit W et\u00a0al (1973) Relief of pain of Fabry\u2019s disease by diphenylhydantoin. Neurology 23:871\u2013875","journal-title":"Neurology"},{"key":"1238_CR9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","volume":"39","author":"Filling-Katz","year":"1989","unstructured":"Filling-Katz MR, Merrick HF, Fink JK et\u00a0al (1989) Carbamazepine in Fabry\u2019s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 39:598\u2013600","journal-title":"Neurology"},{"key":"1238_CR10","doi-asserted-by":"crossref","unstructured":"Ries M, Mengel E, Kutschke G et\u00a0al (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J\u00a0Inherit Metab Dis 26:413\u2013414","DOI":"10.1023\/A:1025127723729"},{"key":"1238_CR11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","volume":"11","author":"Burlina","year":"2011","unstructured":"Burlina AP, Sims KB, Politei JM et\u00a0al (2011) Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 11:61","journal-title":"BMC Neurol"},{"key":"1238_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM et\u00a0al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703\u2013710","journal-title":"Muscle Nerve"},{"key":"1238_CR13","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR et\u00a0al (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease. N\u00a0Engl J Med 345:9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"1238_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N et\u00a0al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"1238_CR15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","volume":"4","author":"Desnick","year":"2004","unstructured":"Desnick RJ (2004) Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase\u00a0A orphan products and one FDA approval. Expert Opin Biol Ther 4:1167\u20131176","journal-title":"Expert Opin Biol Ther"},{"key":"1238_CR16","first-page":"CD006663","volume":"Rev","author":"El","year":"2010","unstructured":"El Dib RP, Pastores GM (2010) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev:CD006663","journal-title":"Cochrane Database Syst"},{"key":"1238_CR17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"Hilz","year":"2004","unstructured":"Hilz MJ, Brys M, Marthol H et\u00a0al (2004) Enzyme replacement therapy improves function of C-, A\u03b4-, and A\u03b2-nerve fibers in Fabry neuropathy. Neurology 62:1066\u20131072","journal-title":"Neurology"},{"key":"1238_CR18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G et\u00a0al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy: a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535\u2013542","journal-title":"Clin J Pain"},{"key":"1238_CR19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P et\u00a0al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374:1986\u20131996","journal-title":"Lancet"},{"key":"1238_CR20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","volume":"99","author":"Sirrs","year":"2010","unstructured":"Sirrs S, Clarke JT, Bichet DG et\u00a0al (2010) Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Mol Genet Metab 99:367\u2013373","journal-title":"Mol Genet Metab"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-012-1238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-012-1238-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-012-1238-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:24:08Z","timestamp":1559093048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-012-1238-1"}},"subtitle":["Diagnostik und Therapie","Diagnosis and treatment"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s00482-012-1238-1","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}